Navigation Links
Golub Capital Provides Financing to Support The Recapitalization of Integrated DNA Technologies, Inc.

NEW YORK, April 23 /PRNewswire/ -- Golub Capital today announced that it has provided $12.0 million of senior subordinated debt to support the recapitalization and ongoing growth of Integrated DNA Technologies, Inc. ("IDT").  This transaction marks the first investment made by GC 2009 Mezzanine Partners, L.P., which is Golub Capital's sixth fund dedicated to middle market mezzanine debt financings.  The fund targets attractive net returns by investing primarily in mezzanine and second lien debt investments in U.S. middle market companies.

Headquartered in Coralville, Iowa, IDT is the leading supplier of custom nucleic acids in the United States, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. IDT's primary business is the manufacture of custom, synthetic DNA and RNA oligonucleotides and genes. Today, IDT synthesizes and ships an average of 36,000 custom oligos per day to more than 86,000 customers worldwide. IDT's manufacturing locations include facilities in Coralville, Iowa; San Diego, California; and Leuven, Belgium.

"We are excited to have the opportunity to partner with the IDT management team and to begin a lending relationship with the Company," commented Senior Managing Director Andrew Steuerman. "IDT has built its market leading position over the last 25 years by delivering exceptional product quality and building longstanding customer relationships."

"This is our first time working with Golub Capital," noted Dr. Joseph Walder, IDT's founder and CEO.  "The financing provided by Golub Capital will help ensure that IDT maintains a strong balance sheet and has the flexibility necessary to pursue our ambitious plans for the future."

About Golub Capital

With $4 billion in capital, Golub Capital is a leading provider of financing solutions for the middle market, including one-loan financings (through the firm's proprietary GOLD facility), senior, second lien and subordinated debt, preferred stock and co-investment equity. The firm also underwrites and syndicates senior credit facilities up to $200 million. Golub Capital's hold sizes range from $10 million to $75 million per transaction.  Golub Capital was ranked by Thomson Reuters Loan Pricing Corporation as the #1 Traditional Middle Market Bookrunner for 2009.  For two years in a row, Golub Capital was named "Middle Market Lender of the Year" by Buyouts Magazine for achievements in 2009 and 2008.  Other honors awarded to Golub Capital include being named "2009 Mezzanine Financing Agent of the Year" and "2008 Financing Firm of the Year" by M&A Advisor and "2008 M&A Lender of the Year" by ACG's Mergers & Acquisitions. Golub Capital is a national firm with offices in Chicago, New York and Atlanta. For more information, please visit the firm's website at

Golub Capital Incorporated (and its various affiliates) creates and manages multiple private funds.  One of its affiliates, GC Advisors LLC is an investment advisor registered with the United States Securities and Exchange Commission. 

SOURCE Golub Capital
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC
2. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
3. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
4. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
5. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
6. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
7. Osteotech to Present at Roth Capital Partners 2007 New York Investor Conference
8. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
9. Luminex Corporation to Present at Americas Growth Capital Emerging Growth Conference
10. Altheus Therapeutics Secures $3.6 Million in Venture Capital
11. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
Post Your Comments:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
Breaking Biology Technology:
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):